(VIANEWS) – MEDISTIM (MEDI.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MEDISTIM (MEDI.OL) | kr169.50 | 2.62% | 28.31% |
| GUERBET (GBT.PA) | €32.85 | 1.42% | 8.14% |
| VETOQUINOL (VETO.PA) | €99.50 | 1% | 8.99% |
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.38% | 5.31% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MEDISTIM (MEDI.OL)
2.62% Forward Dividend Yield and 28.31% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation of fragile or calcified vessels; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.7.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 29.74. Meaning, the purchaser of the share is investing kr29.74 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.31%.
Volatility
MEDISTIM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.31%, a negative 0.30%, and a positive 1.65%.
MEDISTIM’s highest amplitude of average volatility was 1.48% (last week), 1.49% (last month), and 1.65% (last quarter).
Volume
Today’s last reported volume for MEDISTIM is 1 which is 99.99% below its average volume of 14426.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2024, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.62%.
More news about MEDISTIM.
2. GUERBET (GBT.PA)
1.42% Forward Dividend Yield and 8.14% Return On Equity
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.
Earnings Per Share
As for profitability, GUERBET has a trailing twelve months EPS of €-3.35.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.14%.
Moving Average
GUERBET’s worth is below its 50-day moving average of €34.75 and above its 200-day moving average of €32.44.
More news about GUERBET.
3. VETOQUINOL (VETO.PA)
1% Forward Dividend Yield and 8.99% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.97.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 20.02. Meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.99%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 4, 2024, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 1%.
More news about VETOQUINOL.
4. SARTORIUS STED BIO (DIM.PA)
0.38% Forward Dividend Yield and 5.31% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.31%.
More news about SARTORIUS STED BIO.
